摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3,9-dibenzyl-6,12-bis(4-benzyloxyphenyl)-1,5,7,11-tetrakishydroxymethyl-3,9-diazahexacyclo[6.4.0.0(2.7).0(4.11).0(5.10)]dodecane | 1053418-49-7

中文名称
——
中文别名
——
英文名称
3,9-dibenzyl-6,12-bis(4-benzyloxyphenyl)-1,5,7,11-tetrakishydroxymethyl-3,9-diazahexacyclo[6.4.0.0(2.7).0(4.11).0(5.10)]dodecane
英文别名
[3,9-Dibenzyl-5,7,11-tris(hydroxymethyl)-6,12-bis(4-phenylmethoxyphenyl)-3,9-diazapentacyclo[6.4.0.02,7.04,11.05,10]dodecan-1-yl]methanol
3,9-dibenzyl-6,12-bis(4-benzyloxyphenyl)-1,5,7,11-tetrakishydroxymethyl-3,9-diazahexacyclo[6.4.0.0(2.7).0(4.11).0(5.10)]dodecane化学式
CAS
1053418-49-7
化学式
C54H54N2O6
mdl
——
分子量
827.033
InChiKey
RPGPOZLJCMVINV-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    6.6
  • 重原子数:
    62
  • 可旋转键数:
    16
  • 环数:
    12.0
  • sp3杂化的碳原子比例:
    0.33
  • 拓扑面积:
    106
  • 氢给体数:
    4
  • 氢受体数:
    8

反应信息

  • 作为反应物:
    描述:
    3,9-dibenzyl-6,12-bis(4-benzyloxyphenyl)-1,5,7,11-tetrakishydroxymethyl-3,9-diazahexacyclo[6.4.0.0(2.7).0(4.11).0(5.10)]dodecane三氟乙酸 作用下, 以 茴香硫醚 为溶剂, 以32%的产率得到3,9-dibenzyl-1,5,7,11-tetrakishydroxymethyl-6,12-bis(4-hydroxyphenyl)-3,9-diazapentacyclo[6.4.0.0(2,7).0(4,11).0(5,10)]dodecane
    参考文献:
    名称:
    Novel structure–activity relationships and selectivity profiling of cage dimeric 1,4-dihydropyridines as multidrug resistance (MDR) modulators
    摘要:
    Synthesized series of cage dimeric 1,4-dihydropyridines have been systematically evaluated as MDR modulators in in vitro assays to investigate structure-dependent selectivity properties of inhibiting most cancer-relevant efflux pump proteins. Structure-activity relationships of each P-glycoprotein (P-gp) and multidrug resistance associated protein (MRP) 1 and MRP2 inhibition are discussed and prove to be mainly determined by certain aromatic substitution patterns. The characterization of breast cancer resistance protein (BCRP) inhibition results in the discovery of benzyloxy substituted derivatives as selective P-gp inhibitors. (C) 2010 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmc.2010.06.004
  • 作为产物:
    描述:
    tetraethyl 3,9-dibenzyl-6,12-bis(4-benzyloxyphenyl)-3,9-diazahexacyclo[6.4.0.0(2.7).0(4.11).0(5.10)]dodecane-1,5,7,11-tetracarboxylate 在 lithium aluminium tetrahydride 作用下, 以 四氢呋喃 为溶剂, 生成 3,9-dibenzyl-6,12-bis(4-benzyloxyphenyl)-1,5,7,11-tetrakishydroxymethyl-3,9-diazahexacyclo[6.4.0.0(2.7).0(4.11).0(5.10)]dodecane
    参考文献:
    名称:
    Novel structure–activity relationships and selectivity profiling of cage dimeric 1,4-dihydropyridines as multidrug resistance (MDR) modulators
    摘要:
    Synthesized series of cage dimeric 1,4-dihydropyridines have been systematically evaluated as MDR modulators in in vitro assays to investigate structure-dependent selectivity properties of inhibiting most cancer-relevant efflux pump proteins. Structure-activity relationships of each P-glycoprotein (P-gp) and multidrug resistance associated protein (MRP) 1 and MRP2 inhibition are discussed and prove to be mainly determined by certain aromatic substitution patterns. The characterization of breast cancer resistance protein (BCRP) inhibition results in the discovery of benzyloxy substituted derivatives as selective P-gp inhibitors. (C) 2010 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmc.2010.06.004
点击查看最新优质反应信息

文献信息

  • Novel Insight in Structure−Activity Relationship and Bioanalysis of P-Glycoprotein Targeting Highly Potent Tetrakishydroxymethyl Substituted 3,9-Diazatetraasteranes
    作者:Claudius Coburger、Jörg Wollmann、Christiane Baumert、Martin Krug、Josef Molnár、Hermann Lage、Andreas Hilgeroth
    DOI:10.1021/jm800480y
    日期:2008.9.25
    Novel 3,9-diazatetraasteranes have been synthesized with varied aromatic substitution patterns and evaluated as P-glycoprotein (P-gp) inhibitors. Structure-activity relationships (SAR) are discussed in relation to determined physicochemical properties. The potential to induce P-gp expression has been evaluated in cancer cell lines. The bioanalytical results indicate favorable noninducing properties compared to P-gp inducing drug standard.
  • Novel structure–activity relationships and selectivity profiling of cage dimeric 1,4-dihydropyridines as multidrug resistance (MDR) modulators
    作者:Claudius Coburger、Jörg Wollmann、Martin Krug、Christiane Baumert、Marianne Seifert、Joséf Molnár、Hermann Lage、Andreas Hilgeroth
    DOI:10.1016/j.bmc.2010.06.004
    日期:2010.7
    Synthesized series of cage dimeric 1,4-dihydropyridines have been systematically evaluated as MDR modulators in in vitro assays to investigate structure-dependent selectivity properties of inhibiting most cancer-relevant efflux pump proteins. Structure-activity relationships of each P-glycoprotein (P-gp) and multidrug resistance associated protein (MRP) 1 and MRP2 inhibition are discussed and prove to be mainly determined by certain aromatic substitution patterns. The characterization of breast cancer resistance protein (BCRP) inhibition results in the discovery of benzyloxy substituted derivatives as selective P-gp inhibitors. (C) 2010 Elsevier Ltd. All rights reserved.
查看更多